Seeking Alpha

Positive Ad Comm opinion for Teva's Seasonique

  • The EMA's Committee for Medicinal Products for Human Use issues a positive opinion regarding the marketing authorization of Teva's (TEVA) extended-regimen oral contraceptive Seasonique (levonorgestrel/ethinyl estradiol). The committee's positive vote clears the way to a product launch in selected European countries by the end of this year.
  • Seasonique is a regimen that contains 84 active pills comprised of levonorgestrel/ethinyl estradiol followed by seven days of ethinyl estradiol tablets. These are used in the seven day regimen instead of placebo to allow women to have four scheduled periods per year while lessening the withdrawal symptoms caused by a sudden drop in hormones.
Comments (1)
  • Patent News
    , contributor
    Comments (1404) | Send Message
     
    TNXP and EVOK are next
    6 Jul 2014, 02:58 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs